Scynexis Transfers Brexafemme New Drug Application to GSK
MT Newswires Live
Nov 19
Scynexis (SCYX) said Wednesday it has completed the transfer of the new drug application for Brexafemme, or ibrexafungerp, to GSK (GSK).
The transfer allows GSK to begin working with the US Food and Drug Administration on a plan to relaunch Brexafemme for vulvovaginal candidiasis and refractory vulvovaginal candidiasis in the US, Scynexis Chief Executive Officer David Angulo said.
Following a relaunch, Scynexis said it could receive up to $145.5 million in annual net sales milestones as well as low to mid-single-digit royalties on net sales.
Shares of Scynexis were up over 5% in recent Wednesday premarket activity, while GSK was down 0.5%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.